|
| 37939133 | ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis. | Clin Cancer Res | 2024 |
| 38015629 | Age-related loss of Notch3 underlies brain vascular contractility deficiencies, glymphatic dysfunction, and neurodegeneration in mice. | J Clin Invest | 2024 |
| 36759014 | IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. | J Immunother Cancer | 2023 |
| 37860079 | Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas. | Adv Oncol | 2023 |
| 37847564 | Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. | J Clin Invest | 2023 |
| 36959214 | STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. | Nat Commun | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 36949040 | Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. | Nat Commun | 2023 |
| 37142373 | Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. | Lancet Oncol | 2023 |
| 37164210 | Validating the VS-5 Score for Predicting Outcomes After Vestibular Schwannoma Resection in an Institutional Cohort. | World Neurosurg | 2023 |
| 36652630 | Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. | Mol Cancer Res | 2023 |
| 36647828 | Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. | J Clin Invest | 2023 |
| 36778274 | Clinical outcomes for pleomorphic xanthoastrocytoma patients: an institutional experience. | Res Sq | 2023 |
| 36711497 | B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression. | Res Sq | 2023 |
| 36826993 | Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes. | Clin Cancer Res | 2023 |
| 35149861 | Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2022 |
| 35724885 | Mean Brain Dose Remains Uninfluenced by the Lesion Number for Gamma Knife Stereotactic Radiosurgery for 10+ Metastases. | World Neurosurg | 2022 |
| 35784281 | Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. | Front Immunol | 2022 |
| 35552677 | Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. | Clin Cancer Res | 2022 |
| 36011015 | Next Steps for Immunotherapy in Glioblastoma. | Cancers (Basel) | 2022 |
| 35316217 | Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. | JCI Insight | 2022 |
| 32527113 | Management of glioblastoma: a perspective from Mexico. | Chin Clin Oncol | 2021 |
| 37476488 | Gene Therapy for the Treatment of Malignant Glioma. | Adv Oncol | 2021 |
| 33692132 | A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. | Sci Transl Med | 2021 |
| 34917265 | Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas. | Oncotarget | 2021 |
| 34948178 | The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. | Int J Mol Sci | 2021 |
| 35121903 | ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2021 |
| 34993480 | Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner. | Neurooncol Adv | 2021 |
| 34433651 | TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. | Clin Cancer Res | 2021 |
| 34214495 | Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. | Lancet Oncol | 2021 |
| 33223030 | Role of Resection in Glioblastoma Management. | Neurosurg Clin N Am | 2021 |
| 33456708 | Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy. | Oncotarget | 2021 |
| 33272983 | Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. | Clin Cancer Res | 2021 |
| 32991668 | Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. | J Exp Med | 2021 |
| 31443114 | TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway. | Int J Cancer | 2020 |
| 35592772 | Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy. | J Cell Immunol | 2020 |
| 31967642 | Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients? | Neuro Oncol | 2020 |
| 31931632 | Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. | Br J Neurosurg | 2020 |
| 33222970 | Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. | J Clin Neurosci | 2020 |
| 32615600 | Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. | Neuro Oncol | 2020 |
| 32528131 | Ribosomal protein S11 influences glioma response to TOP2 poisons. | Oncogene | 2020 |
| 32554515 | Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. | Clin Cancer Res | 2020 |
| 32384274 | Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. | J Neurosurg | 2020 |
| 32430477 | CD8<sup>+</sup> T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. | Clin Cancer Res | 2020 |
| 32257285 | Evaluation of patient education materials for stereotactic radiosurgery from high-performing neurosurgery hospitals and professional societies. | Neurooncol Pract | 2020 |
| 29660011 | Craniotomy and Survival for Primary Central Nervous System Lymphoma. | Neurosurgery | 2019 |
| 31812138 | Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma? | J Neurosurg | 2019 |
| 31407129 | Extent of resection and survival for oligodendroglioma: a U.S. population-based study. | J Neurooncol | 2019 |
| 31374547 | Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model. | J Neurosurg | 2019 |
| 31598900 | Immunotherapy Against Gliomas: is the Breakthrough Near? | Drugs | 2019 |